Developing innovative antibody-based therapies for the treatment of kidney diseases.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $110.8M
Founded date: 2007
Investors 4
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
| - | MRL Ventur... | mrlv.com |
| - | Lux Capita... | luxcapital... |
| - | Cycad Grou... | cycadvc.co... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 05.10.2017 | Series C | $46.7M | - |
| 02.10.2014 | Series B | $30M | - |
| 02.12.2013 | Series A | $8.1M | - |
| 09.11.2012 | Series A | $26M | - |
Mentions in press and media 24
| Date | Title | Description | Source |
| 06.10.2017 | Term Sheet — Friday, October 6 | DAYS OF CHANGE Happy Friday, Term Sheet readers. Paid Content You can't secure what you can't see ... | fortune.co... |
| 05.10.2017 | Visterra Closes $46.7 Million Series C Financing | Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope platform to ide... | citybizlis... |
| 05.10.2017 | Visterra Closes $46.7M Series C Financing | Visterra, Inc., a Cambridge, MA – based clinical-stage biotechnology company, completed a Series C f... | finsmes.co... |
| 05.10.2017 | Visterra adds $24M to series C to take flu drug to phase 2b | Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. Th... | fiercebiot... |
| 05.10.2017 | Visterra adds $24M to series C to take flu drug to phase 2b | Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. Th... | fiercebiot... |
| 05.10.2017 | Visterra Announces $46.7M Series C Funding | CAMBRIDGE, MA, Visterra, a biotech company, has closed its Series C funding round at $46.7 million... | vcnewsdail... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Ac... | medcitynew... |
| 02.10.2014 | Visterra bringing influenza immunotherapy into Phase 2 with ... | The financing was led by two new investors: Merck Research Labs Venture Fund and Singapore-based Ver... | medcitynew... |
| 02.10.2014 | Visterra Completes $30M Series B Financing | Visterra, Inc., a Cambridge, MA-based biotechnology company that uses its proprietary technology pla... | finsmes.co... |
| 02.10.2014 | Visterra Closes $30M Series B Financing | CAMBRIDGE, MA, Biotechnology company has completed a $30 million Series B financing round. >&g... | vcnewsdail... |
Show more